LPA81

N/A

Report date: 2023/03/22 13:43:40
NME

Base Information

Drug NameLPA81
Drug Alias NameLPA81LPA-81
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionBcr-Abl tyrosine kinase degraders
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVersiti Blood Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesVersiti Blood Research Institute
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A